Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers

The current standard of adjuvant therapies for patients with early stage non-small-cell lung cancers largely depends on the stage of disease. Liquid biopsy for circulating tumor DNA (ctDNA) has the potential to detect minimal residual disease, depict genomic evolution, guide precision medicine to in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Transl Med
Autors principals: Li, Bob T., Stephens, Dennis, Chaft, Jamie E., Rudin, Charles M., Jones, David R., Rusch, Valerie W., Rimner, Andreas, Isbell, James M.
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2017
Matèries:
Perspective
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5733322/
https://ncbi.nlm.nih.gov/pubmed/29285512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2017.09.02
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars